Public Release: 

Forsyth study provides new insight in the fight against Sjögren's syndrome

Forsyth Institute

CAMBRIDGE, Mass., Dec.14 - Sjögren's syndrome is the second most common autoimmune disease affecting four million Americans--yet treatments are limited due to a lack of knowledge about its causes. A new study from the Forsyth Institute is helping to shed light on what happens in the development and the life cycle of the disease. This study is one of the first to define the immune-regulatory mechanisms operating in Sjögren's syndrome and provides a new foundation for fighting the disease.

Two specific proteins in the body, programmed death-ligand 1 (PD-L1) along with PD1 have been found to work together to suppress both protective immunity and autoimmune responses to prevent organ damage. According to research published in Scientific Reports, scientists at Forsyth led by Dr. Qing Yu have shown that blockade of the PD-L1-PD-1 pathway made the autoimmune response worse and accelerated the development of Sjögren's syndrome.

The hallmark symptoms of Sjögren's syndrome are dry mouth and dry eyes. However, the disease also affects many other organs and causes an array of health complications including B cell lymphoma. In this study, the research team investigated the role of PD-L1 in Sjögren's by inhibiting its function in a common disease model (non-obese diabetic mice). They found that PD-L1 hinders the development and onset of the disease.

The study, titled, "Endogenous programmed death ligand-1 restrains the development and onset of Sj?gren's syndrome in non-obese diabetic mice," is published on December 14th in Scientific Reports. This study investigated the previously un-explored role of the PD-L1 pathway in Sjögren's syndrome. Using an experimental mouse disease model, Dr. Yu and her colleagues characterized how the pathway serves to impede and limit the autoimmune responses and the pathologic development of this disease. This novel finding is one of the first to define the immune-regulatory mechanisms operating in Sjögren's syndrome, and provides initial foundation and justification for harnessing the immune-inhibitory pathways, such as PD-L1-PD-1, to combat this high-impact autoimmune disease.

###

This research is supported by grants from the National Institutes of Health R01 DE023838, P30 DE020751.

About The Forsyth Institute

Founded in 1910, the Forsyth Institute is the only independent research organization in the United States dedicated to understanding the important connections between oral health and overall wellness. Forsyth scientists are shaping the direction of personalized medicine through pioneering biomedical research and its direct application to new diagnostics, devices and therapies. Forsyth combines its expertise in oral and associated systemic diseases with a relentless drive to ask - and answer - critical questions about how to best alleviate daily health challenges for billions. Forsyth is a not-for-profit organization that is also committed to treating underserved populations in local communities and on a national and global scale. To learn more about Forsyth, visit http://www.forsyth.org.

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.